A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy


Autoři: Katsumaro Kubo aff001;  Koichi Wadasaki aff002;  Daisuke Komichi aff003;  Tamito Sasaki aff003;  Hiroyasu Yamada aff003;  Yasuhiro Matsugu aff004;  Toshiyuki Itamoto aff004;  Mihoko Doi aff005;  Katsunori Shinozaki aff005
Působiště autorů: Department of Radiation Oncology, Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima-shi, Hiroshima, Japan aff001;  Department of Radiation Oncology, Hiroshima Prefectural Hospital, Hiroshima-shi, Hiroshima, Japan aff002;  Department of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima-shi, Hiroshima, Japan aff003;  Department of Surgery, Hiroshima Prefectural Hospital, Hiroshima-shi, Hiroshima, Japan aff004;  Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima-shi, Hiroshima, Japan aff005
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227305

Souhrn

We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma and to identify the role of radiation therapy. We assessed all patients who were diagnosed with pancreatic ductal carcinoma from January 2011 to December 2017. A total of 342 patients were enrolled. Thirteen, 131, 36, and 162 patients had stage I, II, III, and IV disease, respectively (UICC TNM, 7th edition). Among the patients with stages I–III disease, 94 underwent surgery, and the median overall survival (OS) was 33 months. Of patients with stages I–III disease who were not suitable for surgery, 58 patients received chemotherapy, and the median OS was 12 months. Among them, 17 patients received chemoradiotherapy added on chemotherapy and their OS was significantly better than that of patients who received chemotherapy alone. Of patients with stage IV disease, 111 received chemotherapy, and the median OS was 6 months. This study evaluated the demand, role, and outcome of each treatment modality and demonstrated a single institution experience of treatment of pancreatic ductal carcinoma. The demand and role of radiation therapy remained small; however, radiation therapy might have some importance as a local treatment.

Klíčová slova:

Cancer chemotherapy – Cancer treatment – Chemotherapy – Metastasis – Pancreatic cancer – Radiation therapy – Surgical and invasive medical procedures – Surgical oncology


Zdroje

1. National Cancer Center, Center for Cancer Control and Information Services. Latest cancer statistics 2017. Available from URL: http://ganjoho.jp/reg_stat/statistics/stat/summary.html.

2. Sen N, Falk S, Abrams R. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol. 2014; 26: 551–559.

3. Palta M, Willet CG, Czito BG. Pancreatic cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors: Principles and practice of radiation oncology. 6th ed, Philadelphia: Lippincott Williams & Wilkins: 1189–1202.

4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817–1825. doi: 10.1056/NEJMoa1011923 21561347

5. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with Gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013; 31: 23–29. doi: 10.1200/JCO.2012.44.4869 23213101

6. Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-Paclitaxel plus Gemcitabine versus Gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015; 20: 143–150. doi: 10.1634/theoncologist.2014-0394 25582141

7. Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, et al. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis. Pancreas. 2017; 46: 595–604. doi: 10.1097/MPA.0000000000000816 28426492

8. National Comprehensive Cancer Network Inc NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma version 2. 2018. Available from URL: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#pancreatic.

9. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110: 47–55. doi: 10.1002/cncr.22735 17538975

10. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25: 326–331. doi: 10.1200/JCO.2006.07.5663 17235048

11. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012; 118: 3026–3035. doi: 10.1002/cncr.26633 22020923

12. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, et al. Induction Gemcitabine and Oxaliplatin therapy followed by a twice-weekly infusion of Gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. Cancer. 2013; 119: 277–284. doi: 10.1002/cncr.27736 22778019

13. Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, et al. Phase 2 trial of induction Gemcitabine, Oxaliplatin, and Cetuximab followed by selective Capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014; 88: 837–844. doi: 10.1016/j.ijrobp.2013.12.030 24606850

14. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2015; 94: 755–765. doi: 10.1016/j.ijrobp.2015.12.003 26972648

15. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011; 79: 158–162. doi: 10.1016/j.ijrobp.2009.10.043 20399035

16. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012; 82: 595–601.

17. de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, James Moser A, et al. Stereotactic body radiotherapy for unresectable pancreatic cancer: a nationwide review. Cancer. 2017; 123: 4158–4167. doi: 10.1002/cncr.30856 28708929

18. Zhu X, Ju X, Cao Y, Shen Y, Cao F, Qing S, et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys. 2019; 104: 101–110. doi: 10.1016/j.ijrobp.2019.01.075 30684663

19. Jethwa KR, Tryggestad EJ, Whitaker TJ, Giffey BT, Kazemba BD, Neben-Wittich MA, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol. 2018; 3: 314–321. doi: 10.1016/j.adro.2018.04.003 30202800

20. Butturini G, Stocken DD, Wente MN, Jeekel H, Kinkenbijl JH, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008; 143:75–83. doi: 10.1001/archsurg.2007.17 18209156

21. Katz MHG, Shi Q, Ahmad SA, Herman JM, Marsh Rbe W, Collisson E, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016; 151: e161137. doi: 10.1001/jamasurg.2016.1137 27275632

22. Mellon EA, hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015; 54: 979–985. doi: 10.3109/0284186X.2015.1004367 25734581

23. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al. Alliance for clinical oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017; 17:505. doi: 10.1186/s12885-017-3441-z 28750659


Článek vyšel v časopise

PLOS One


2019 Číslo 12